Category Access Gap

Pneumonia vaccine is not cost effective in middle income countries

Sofosbuvir+Ledipasvir FDC generic market prices in India 26th of April 2016

How the MDGs gave up on measuring access to medicines

Drug price increases are common in the USA

Only 36% of people with cancer in India receive any form of treatment

Dealing with intellectual property issues linked to affordability and access to medicines, included in the WHO Essential Medicines List (EML).

Hedge-fund style Pharmaceutical strategies impact patients the most, but have less impact on health systems and insurance companies than do smaller price increases on widely used drugs.

Impact on poverty in India by household expenditure on health care

Voluntary licensing and tiered pricing are ineffective and help Gilead Sciences maintain market dominance – essay by Médecins du Monde

low-cost access to new (interferone-free) hepatitis c therapy regimen is feasible for 100-250 US$ per person

Sofosbuvir reference collection

March-in rights on Federally funded research have not been effective at securing access to medicines. Non-exclusive licensing should be pursued instead.

Out-of-pocket expenditure (on healthcare) is higher in the developing world, leaving many people exposed to the high costs of healthcare.

Pharma patient assistance programs can act as industry subsidies.

Pharma patient assistance programs do not have enough data to support them.

Large group of leukaemia doctors denounce high drug prices

NCDs growing in LMICs, converging with infectious diseases

Generic production results in price drop of >80% for widely used drugs

Possible to produce Hep-C drugs for far lower, affordable price

UN Special Rapporteur’s mission to GSK (responsibility of Pharma to uphold right to health)

COUNTERING: “only 1-4% of essential medicines are patented”

Review of secondary patents (prodrugs, polymorphs, salts)

Tiered-pricing is not a good strategy for improving A2M

Dutch customs officials delay generics shipment for months due to EU laws on counterfeits (2009)

USTR Special 301 report (still) criticising use of TRIPS flexibilities

Examples of US trade bullying after Countries use Compulsory Licenses

One-third of the world don’t have regular access to medicines

Generic ARVs save PEPFAR $323 mil per year

Thai-US FTA (TRIPS+) will increase Medicine Price Index by 32%

UN Human Rights Council reaffirms access to medicines as essential to right to health (most recent)

Only 1% of global pharma income is from Low-Income Countries

Use of Compulsory Licenses decreasing – Doha declaration insufficient

Yale’s Dean of Public Health: Yale did not lose money due to Stavudine patent concession

Humanitarian NGOs rely on generics